CX Institutional Has $9.41 Million Stock Holdings in Amgen Inc. $AMGN

CX Institutional reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 32.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 25,985 shares of the medical research company’s stock after selling 12,252 shares during the quarter. CX Institutional’s holdings in Amgen were worth $9,410,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC increased its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares in the last quarter. Tower View Wealth Management LLC grew its stake in shares of Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the period. Manning & Napier Advisors LLC grew its stake in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in Amgen in the 4th quarter valued at about $34,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 1.6%

NASDAQ AMGN opened at $378.87 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $204.48 billion, a P/E ratio of 26.37, a PEG ratio of 3.90 and a beta of 0.41. The business has a fifty day simple moving average of $357.39 and a 200 day simple moving average of $354.35. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $398.00.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 70.15%.

Analyst Ratings Changes

AMGN has been the topic of several recent research reports. UBS Group increased their price target on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Weiss Ratings cut Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price target on shares of Amgen in a research note on Monday, July 6th. Piper Sandler restated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Finally, Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $357.00.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s second-quarter outlook calls for newer medicines to offset declines in parts of its legacy portfolio. Analysts are also assessing whether the company can exceed quarterly earnings expectations, which could support the shares if management delivers strong results or raises its outlook. Amgen Q2 preview: growth from newer drugs to offset legacy portfolio declines Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
• Positive Sentiment: An early-stage AMG 127 study signals Amgen’s expansion into type 2 diabetes, potentially opening another large market. However, the program remains preliminary and is not yet a near-term revenue driver. Amgen’s AMG 127 Trial Signals a New Push Into Type 2 Diabetes
• Neutral Sentiment: Amgen obtained a license to Kaléo’s patented auto-injector technology. The deal could improve drug-device capabilities and patient convenience, but financial terms were undisclosed, limiting its immediate valuation impact. Kaléo Announces License Agreement with Amgen for Auto-Injector Technology
• Negative Sentiment: Amgen is investigating a data breach involving patient health information and proprietary company data. The scope and consequences remain unclear, but potential regulatory costs, litigation, remediation expenses and reputational damage are significant risks. This appears to be the principal near-term overhang ahead of earnings. Amgen contends with data breach, exposing patient information Amgen reveals material cyber breach with patient data stolen

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.